Alexion Pharmaceuticals (ALXN) : Traders are bullish on Alexion Pharmaceuticals (ALXN) as it has outperformed the S&P 500 by a wide margin of 4.92% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.29%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2.23% in the last 1 week, and is up 8.44% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3.27% and the 50-Day Moving Average is 2.07%. Alexion Pharmaceuticals, Inc. has dropped 7.67% during the last 3-month period . Year-to-Date the stock performance stands at -32.58%.
Alexion Pharmaceuticals (NASDAQ:ALXN): On Fridays trading session , Opening price of the stock was $130.41 with an intraday high of $131.3. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $127.7. However, the stock managed to close at $128.6, a loss of 1.38% for the day. On the previous day, the stock had closed at $130.4. The total traded volume of the day was 1,895,466 shares.
Also, Barclays maintains its rating on Alexion Pharmaceuticals (NASDAQ:ALXN). The global brokerage major lowers the current price target from $165 per share to $150 per share. Analysts at the Barclays have a current rating of Equal-weight on the shares. The rating by the firm was issued on July 29, 2016.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.